Trials / Recruiting
RecruitingNCT07408219
A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
RELIEF: Remibrutinib in Chronic Spontaneous Urticaria: Early Real World Effectiveness and Satisfaction Survey
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 350 (estimated)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This is a United States (US) based, prospective, non-interventional, provider-referral study to evaluate the real-world effectiveness and patient-centered outcomes of remibrutinib in chronic spontaneous urticaria (CSU) patients using validated patient reported outcome (PRO) tools.
Conditions
Timeline
- Start date
- 2026-01-17
- Primary completion
- 2026-03-31
- Completion
- 2026-03-31
- First posted
- 2026-02-13
- Last updated
- 2026-03-05
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT07408219. Inclusion in this directory is not an endorsement.